Literature DB >> 3669151

Characterization of in vitro transcription and transcriptional products of measles virus.

J Ray1, R S Fujinami.   

Abstract

Ribonucleoprotein complexes isolated from measles virus-infected HeLa cells contained an RNA-dependent RNA polymerase activity that catalyzed the incorporation of ribonucleotides into ribonucleic acid. The ribonucleoprotein complexes were composed of measles virus nucleoprotein, phosphoprotein, and a large protein, as well as viral RNA. The kinetics of RNA synthesis at different temperatures, time intervals, and protein, ribonucleotide, and mono- and divalent cation concentrations were analyzed. Enzyme activity was maximum at 4 h at 25 degrees C in the presence of 100 mM Na+-2.5 mM Mg2+-1 mM ribonucleotides. Actinomycin D and alpha-amanitin had no effect on the enzyme activity. Addition of cytoplasmic extracts from uninfected HeLa cells to the reaction mixture did not increase the incorporation of ribonucleotides into RNA. The in vitro synthesized RNAs were characterize by slot blot analysis and quantitated by densitometer scanning. All mRNAs coding for the structural proteins of measles virus were synthesized. Nucleoprotein RNA was the most abundant species made, followed by phosphoprotein, hemagglutinin, fusion protein, matrix protein, and large-protein RNAs. The system described here resulted in the first efficient transcription of measles virus RNA and analysis of products.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3669151      PMCID: PMC255932     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Sequential transcription of the genes of vesicular stomatitis virus.

Authors:  G Abraham; A K Banerjee
Journal:  Proc Natl Acad Sci U S A       Date:  1976-05       Impact factor: 11.205

2.  Studies on the in vitro transcription and translation of vesicular stomatitis virus mRNA.

Authors:  M Breindl; J J Holland
Journal:  Virology       Date:  1976-08       Impact factor: 3.616

3.  Inhibitor of vesicular stomatitis virus transcriptase in purified virions.

Authors:  J Perrault; D T Kingsbury
Journal:  Nature       Date:  1974-03-01       Impact factor: 49.962

4.  Ribonucleic acid transcriptases in Sendai Virions and infected cells.

Authors:  H O Stone; A Portner; D W Kingsbury
Journal:  J Virol       Date:  1971-08       Impact factor: 5.103

5.  Properties of the product synthesized by vesicular stomatitis virus particles.

Authors:  D H Bishop; P Roy
Journal:  J Mol Biol       Date:  1971-06-28       Impact factor: 5.469

6.  Ribonucleic acid polymerase activity in Sendai virions and nucleocapsid.

Authors:  W S Robinson
Journal:  J Virol       Date:  1971-07       Impact factor: 5.103

7.  Primary in vivo transcription of vesicular stomatitis virus and temperature-sensitive mutants of five vesicular stomatitis virus complementation groups.

Authors:  A Flamand; D H Bishop
Journal:  J Virol       Date:  1973-12       Impact factor: 5.103

8.  Complete transcription by the transcriptase of vesicular stomatitis virus.

Authors:  D H Bishop
Journal:  J Virol       Date:  1971-04       Impact factor: 5.103

9.  Ribonucleic acid polymerase in virions of Newcastle disease virus: comparison with the vesicular stomatitis virus polymerase.

Authors:  A S Huang; D Baltimore; M A Bratt
Journal:  J Virol       Date:  1971-03       Impact factor: 5.103

10.  Comparison of the ribonucleic acid polymerases of two rhabdoviruses, Kern Canyon virus and vesicular stomatitis virus.

Authors:  H G Aaslestad; H F Clark; D H Bishop; H Koprowski
Journal:  J Virol       Date:  1971-06       Impact factor: 5.103

View more
  19 in total

1.  Measles virus C protein interferes with Beta interferon transcription in the nucleus.

Authors:  Konstantin M J Sparrer; Christian K Pfaller; Karl-Klaus Conzelmann
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Transcription of human respiratory syncytial virus genome RNA in vitro: requirement of cellular factor(s).

Authors:  S Barik
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

Review 3.  In vitro capping and transcription of rhabdoviruses.

Authors:  Tomoaki Ogino
Journal:  Methods       Date:  2012-06-08       Impact factor: 3.608

4.  The relationship between viral RNA, myelin-specific mRNAs, and demyelination in central nervous system disease during Theiler's virus infection.

Authors:  M Yamada; A Zurbriggen; R S Fujinami
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

5.  Germiston virus transcriptase requires active 40S ribosomal subunits and utilizes capped cellular RNAs.

Authors:  P Vialat; M Bouloy
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

6.  Characterization of an in vitro system for the synthesis of mRNA from human parainfluenza virus type 3.

Authors:  B P De; M S Galinski; A K Banerjee
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

7.  Positive and negative host factors for Sendai virus transcription and their organ distribution in rat.

Authors:  T Takagi; M Iwama; K Seta; T Kanda; T Tsukamoto; S Tominaga; K Mizumoto
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

8.  Detection of virus-specific RNA-dependent RNA polymerase activity in extracts from cells infected with lymphocytic choriomeningitis virus: in vitro synthesis of full-length viral RNA species.

Authors:  F V Fuller-Pace; P J Southern
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

9.  Newly identified minor phosphorylation site threonine-279 of measles virus nucleoprotein is a prerequisite for nucleocapsid formation.

Authors:  Akihiro Sugai; Hiroki Sato; Kyoji Hagiwara; Hiroko Kozuka-Hata; Masaaki Oyama; Misako Yoneda; Chieko Kai
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

10.  Phosphorylation of measles virus nucleoprotein affects viral growth by changing gene expression and genomic RNA stability.

Authors:  Akihiro Sugai; Hiroki Sato; Misako Yoneda; Chieko Kai
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.